ArticleBMC gastroenterology2025
Clinical outcomes of combined transarterial chemoembolization and microwave ablation for hepatic hemangiomas: a comparative analysis of large versus. giant tumors.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND/
aimThis study aimed to evaluate the clinical outcomes of combined transarterial chemoembolization and microwave ablation for hepatic hemangiomas, focusing on whether the benefits of this minimally invasive approach extend equally to giant (≥10 cm) as well as large (5-9.9 cm) lesions.
methodThis retrospective study included 53 patients with hepatic hemangiomas who received this combined treatment from January 2015 to January 2025. Patients were stratified by maximum tumor diameter: large hepatic hemangiomas (n = 38) and giant hepatic hemangiomas (n = 15). Outcomes assessed tumor reduction, tumor response, adverse events, and clinical and psychological symptoms.
resultAmong the 53 patients, the median tumor diameter at baseline was 8.30 cm (range: 5-19.2 cm). The median baseline tumor diameter in the large hepatic hemangiomas group was 7.3 cm (range 5-9.8 cm). In the giant hepatic hemangiomas group, the median baseline tumor diameter was 11.3 cm (range 10-19.2 cm). The median follow-up period was 35 months. Both groups achieved similarly high tumor response, with 100% objective response rate at more than three years post-treatment. Additionally, none of the 53 patients experienced hemolytic adverse effects such as hemoglobinuria or severe renal damage, highlighting the safety of this combined treatment.
conclusionThe combined treatment delivers durable clinical outcomes across the size spectrum of hepatic hemangiomas. Giant lesions also achieved durable control without hemolysis-related complications, supporting this minimally invasive approach as a surgical alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.